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Abstract
Rationale: Idiopathic andheritable pulmonary arterial hypertension
(PAH) are rare but comprise a genetically heterogeneous patient
group. RNA sequencing linked to the underlying genetic architecture
can be used to better understand the underlying pathology by
identifying key signaling pathways and stratify patients more
robustly according to clinical risk.
Objectives: To use a three-stage design of RNA discovery, RNA
validation and model construction, and model validation to define a
set of PAH-associated RNAs and a single summarizing RNA model
score. To define genes most likely to be involved in disease
development, we performed Mendelian randomization (MR)
analysis.
Methods: RNA sequencing was performed on whole-blood
samples from 359 patients with idiopathic, heritable, and
drug-induced PAH and 72 age- and sex-matched healthy volunteers.
The score was evaluated against disease severity markers including
survival analysis using all-cause mortality from diagnosis. MR used
known expression quantitative trait loci and summary statistics
from a PAH genome-wide association study.
Measurements and Main Results:We identified 507 genes with
differential RNA expression in patients with PAH compared with
control subjects. A model of 25 RNAs distinguished PAH with 87%
accuracy (area under the curve 95%confidence interval: 0.791–0.945)
in model validation. The RNA model score was associated with
disease severity and long-term survival (P= 4.663 1026) in PAH.
MR detected an association between SMAD5 levels and PAH disease
susceptibility (odds ratio, 0.317; 95% confidence interval,
0.129–0.776; P= 0.012).
Conclusions: A whole-blood RNA signature of PAH, which
includes RNAs relevant to disease pathogenesis, associates with
disease severity and identifies patients with poor clinical outcomes.
Genetic variants associated with lower SMAD5 expression may
increase susceptibility to PAH.
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Pulmonary arterial hypertension (PAH) is
associated with vasoconstriction and
occlusion of distal pulmonary arteries,
characterized by endothelial damage,
smooth muscle and fibroblast proliferation,
and inflammation. Increased pulmonary
vascular resistance leads to right heart
failure, with survival rates estimated at
52–75% at 5 years, even with modern-day
therapy (1). The rate of deterioration and
response to therapy varies between patients,
driving a search for better predictors of
clinical outcome and tools to inform drug
selection. Molecular profiling using
multiple omics technologies offers greater
granularity than standard clinical
phenotypes for characterizing patients with
PAH and could improve initial risk
stratification, treatment selection, and
monitoring as well as provide insights into
biological pathways not yet targeted by
current therapies (2–4).
Transcriptome profiling through RNA
sequencing permits a comprehensive
analysis of gene expression in tissue samples.
Whole-blood RNA analysis offers an
alternative “liquid biopsy” to lung biopsy,
which carries a high risk in PAH, and can
be performed sequentially. This approach
can also investigate immune mechanisms in
PAH that have recently been highlighted
(5). Previous studies of blood RNA in PAH
have been limited by patient numbers and
the use of microarrays, which are less
sensitive than high-quality RNA
sequencing (RNAseq) and limited by the
probe set of each specific array. A recent
meta-analysis of these microarray studies
identified some consistent differentially
expressed genes not appreciated in
individual studies (6). Explanted lung
tissues from patients with late-stage PAH
have also shown differences in RNA
profiles (7). The results from both studies
remain to be validated in independent
cohorts.
The aim of this study was to
characterize gene pathways associated with
PAH and to assess their association with
disease heterogeneity, specifically in terms of
disease severity and outcomes including
response to vasodilators and mortality, and
genetic background. We compare gene
expression in whole-blood samples from
359 patients with idiopathic, heritable, or
drug-induced PAH from the UK PAH
Cohort study with 72 age- and sex-matched
healthy volunteers without any cardiac or
respiratory disease as control subjects. Using
equal distribution of samples into a three-
stage design, we identified reproducible
RNA expression differences by RNAseq.
Two distinct computational approaches
were used to estimate white blood cell
(WBC) fractions and thus account for the
potential effect of different cell numbers on
gene transcript levels across samples. A
predictive statistical model that combined
gene expression differences performed well
at identifying patients with PAH in a
separate case–control analysis. The RNA-
based score was also associated with disease
severity and clinical outcomes (all-cause
mortality). Enrichment of genetic variants
that determine the levels of PAH RNAs was
detected, implicating these RNAs in the
pathogenesis of the disease.
Methods
Comprehensive methods are included in the
online supplement.
Study Participants and Sample
Analysis
Patients with idiopathic, heritable, or drug-
induced pulmonary arterial hypertension
(referred to throughout as PAH) were
recruited from expert centers across the
UK as part of the PAH Cohort study
(www.ipahcohort.com). In each case,
diagnosis was confirmed by right heart
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This article has a related editorial.
This article has an online supplement, which is accessible from this issue’s table of contents at www.atsjournals.org.
At a Glance Commentary
Scientific Knowledge on the
Subject: Blood transcriptomic
profiles in pulmonary arterial
hypertension have been examined in
small limited studies indicating their
potential utility in differentiating
patients from control subjects and by
clinical phenotypes.
What This Study Adds to the Field:
This study represents the most
comprehensive analysis of whole-blood
RNA profiles in pulmonary arterial
hypertension and identifies and
validates a signature that both
differentiates patients from control
subjects and stratifies patients by
clinical risk and severity. Genetic
analyses (Mendelian randomization)
indicate potential causal roles for some
genes including the TGF-b signaling
molecule SMAD5.
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catheterization following established
international guidelines (1), which
remained unchanged for the duration of
this study. Healthy volunteers were
recruited at the same centers and samples
processed using the same standard
operating procedure at all sites. All
individuals gave written, informed consent
with local ethical committee approval.
Whole blood (3 ml) was collected in
Tempus Blood RNA Tubes, and RNAseq
was performed using established Illumina
methodologies (see online supplement for
further details). Genomics data were
obtained from a published PAH genome-
wide association study (8).
Three hundred fifty-nine patients with
PAH were randomized into three data
analysis groups for RNA discovery
(n= 120), RNA validation (n= 120), and
model validation (n= 119). Each of these
three groups was then compared with an
independent set of age- and sex-matched
healthy volunteers as control subjects
(n= 24 in each set; Table 1 and Figure E1
in the online supplement).
RNAseq Data Analysis
Fastq files (raw reads from RNAseq) were
analyzed using Salmon v0.9.1 (9) and
GENCODE release 28 to produce transcript
abundance estimates that were converted to
gene expression data using tximport in R
with Rstudio (10). Quality control is
detailed in the online supplement.
RNAseq analysis of tissues with mixed
cell types such as blood can be affected
significantly by the cell composition of each
sample. Two different computational
approaches, CIBERsort (11) and quanTIseq
(12), were used to predict WBC profiles
associated with PAH, which were included
as covariates in secondary differential
gene expression analyses (see online
supplement). Differential expression
analysis was performed using edgeR v3.22.5
(13) correcting for the three principal
components, which each explained more
than 1% of the variance in the data set.
Differentially expressed genes were defined
in analyses both with and without WBC
fractions as covariates in distinct discovery
and validation sample sets. These sets were
then combined, and only significant genes
(P, 0.05) directionally consistent in the
initial analyses and meeting false discovery
rate (FDR) multiple test corrections (based
on all detected genes, a= 0.1) in the
combined analysis were taken forward. Five
hundred seven genes meeting these criteria
were considered to generate a model to
distinguish PAH from control subjects.
Subset selection of RNAs that best
distinguish PAH in combination was
performed by least absolute shrinkage and
selection operator (LASSO) regression
analysis, using the glmnet v2.0-18 package
from CRAN, with k-fold cross-validation
(k= 10) selecting the largest value of
lambda such that error is within 1 SE of the
minimum. This produces an RNA score
from a linear weighted combination of the
mRNAs identified by the LASSO analysis.
Receiver operating characteristic analysis
was performed using the pROC v1.14.0
package from Bioconductor (14).
Survival curves from date of diagnostic
right heart catheterization were constructed
using Kaplan-Meier estimates with left
truncation for date of sampling for this
study to correct for survival bias. Differences
in survival estimates were assessed by log-
rank test. RNA scores were also compared
across disease severity markers 6-minute-
walk test (Spearman’s rank) and World
Health Organization (WHO) functional
class (Kruskal-Wallis ANOVA) and by
cardiac biomarkers (circulating BNP [brain
natriuretic peptide] or NT-proBNP
[N-terminal pro-brain natriuretic peptide] as
Table 1. Basic Demographics of Control Subjects and Patients with PAH in Three Analysis Groups and More Detailed Clinical
Characteristics, Including Disease Severity of Patients with PAH as a Cohort
A: RNA Discovery B: RNA Validation C: Model Validation
Control Subjects PAH Control Subjects PAH Control Subjects PAH
Female 17 89 16 80 17 86
Male 7 31 8 40 7 33
Age, yr 43.9 (30.2–53.4) 45.2 (35.7–55) 45.1 (31–53.5) 43.2 (33.3–54.8) 44.4 (31.7–51.6) 47.1 (36.7–61.2)
PAH Patient Characteristics in A, B, and C Median (25th–75th Percentile) or Counts
Age at diagnosis 44.8 (34.3–58.1)
Female/male 255/104
Ethnicity, white/other 314/45
WHO functional class, I/II/III/IV 36/138/155/18
Six-minute-walk distance, m 330 (224.5–411)
Mean pulmonary artery pressure, mm Hg 53 (46–61)
Mean right atrial pressure, mm Hg 8 (6–12)
Pulmonary capillary wedge pressure, mm Hg 10 (7–12)
Q̇, L/min 3.8 (3.05–4.9)
Cardiac index, L/min/m2 2.07 (1.68–2.57)
Pulmonary vascular resistance, Wood units 11.55 (7.93–15.78)
Years since diagnosis sampled 3.95 (1.38–7.7)
Years survived since sampling 3.14 (2.3–3.67)
Years survived since diagnosis 6.99 (4.19–10.88)
Vasoresponders 21
Definition of abbreviations: PAH=pulmonary arterial hypertension; WHO=World Health Organization.
Control subjects are healthy volunteers without any cardiac or respiratory disease.
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available, using cutoffs from European
guidelines for risk assessment (1)).
Functional annotation and enrichment
of the genes associated with PAH was
performed using DAVID (david.ncifcrf.gov)
and Ingenuity Pathway Analysis (IPA) using
in-built FDR corrections for multiple tests.
Mendelian randomization (MR)
analysis using all independent genome-wide
significant whole-blood expression
quantitative trait loci (eQTL) from two
published studies (15, 16) and PAH
association from our published genome-
wide association study (8) was performed
using the TwoSampleMR package (17).
Results
Identification of RNAs Differentially
Expressed in Patients with PAH
Compared with Control Subjects
The three-stage study design is depicted in
Figure 1. Five hundred seven RNAs were
significantly different (P, 0.05) between
PAH and control subjects with directional
concordance in both discovery and
validation analyses (Figure 2 and Table E3)
before and after accounting for WBC
fractions (see METHODS and Tables E1–E3
and Figure E2). All 507 genes were included
after accounting for multiple testing (FDR
a, 0.1, Table E3). None were associated
with exposure to the main PAH therapies
(see online supplement for further details).
These included RNAs in pathways relevant
to PAH; for example, SMAD5 (mothers
against decapentaplegic homolog-5),
encoding a downstream mediator of
signaling of BMPR2 (3), was reduced in
patients with PAH (Figure 2C), consistent
with documented reduced BMPR2
signaling in this condition, and the
transient receptor potential cation channel,
TRPC1 (Figure 2D), also associated with
the development of PH (18), was also
reduced in patients.
A set of differentially expressed RNAs
relevant to PAH pathobiology were selected
for validation of RNAseq quantification by
real-time quantitative PCR, namely, NRG1,
TRPC1, FBLN2, SESN1, SMAD5, and
CCND3. SPAST was also selected for its
stability across samples as a potential
control gene (see METHODS for details). All
real-time quantitative PCR measurements
correlated significantly with RNAseq
quantification (P, 0.05, Spearman’s
rho = 0.3–0.89, Table E4).
Patients and control subjects from the
RNA discovery and validation analyses were
then combined and LASSO analysis was
used to determine the combination of RNAs
that performed best in discriminating
patients with PAH from control subjects in a
single model; this analysis yielded 25 RNAs
(Table E5). The model was then tested in an
independent validation set (n= 119 patients
with PAH and n= 24 control subjects) and
demonstrated an area under the curve
of 0.868 (95% confidence interval,
0.791–0.945) (Figure 3). The optimum
cutoff for identifying PAH with the LASSO
model of 1.768 recognized 88.9% of
patients with 72.2% specificity.
Survival Association of RNA Model in
Clinically Diagnosed Idiopathic and
Heritable PAH
We next examined whether the RNA model
was also associated with patients with the
poorest outcomes, using all 359 patients.
The optimum cutoff (1.910) for identifying
PAH nonsurvivors with the LASSO model
separated patients with PAH into low- and
high-risk groups in survival analysis
(Figures 4A and 4B and E3).
To determine which of the 25
transcripts in the model were responsible
for the association with survival, we
tested each transcript for associations
with all-cause mortality during follow-up.
After FDR correction for multiple testing,
three intronic long noncoding RNAs
(RP4–751H13.6/ATP6V0E2-AS1,
RP4–534N18.4/AL136115.3/Lnc-PTP4A2–13,
RP11–701H24.5/lnc-SNRPN-1:6)
were associated with survival in
all the patients with PAH analyzed
and cutoffs distinguished high- and
low-risk patient subgroups (Table E6
and Figure E4).
To further characterize the RNA
signature, we analyzed its association
with three clinical measures of disease
severity—WHO functional class, exercise
capacity (6-minute-walk), and cardiac
biomarkers (BNP or NT-proBNP). We
found a significant difference in RNA
scores between patients in different WHO
functional classes (P= 0.008; Figure 4C)
and BNP and NT-proBNP levels
(P= 5.103 1024; Figure 4D) and a
significant negative correlation with
exercise capacity (Spearman’s
rho =20.256; P= 8.73 1025).
RNA Profiles in Responders to
Vasodilator Therapy
Several RNAs have been proposed as
biomarkers for identifying vasoresponders
to calcium antagonists using cultured
lymphocytes (19). We compared the
transcriptome of the 17 vasoresponders and
223 nonvasoresponders in the RNA
72 controls 359 PAH patients
Age- and sex-
matching of
controls
RNA discovery RNA validation model testing
Randomized into 3 groups
119 PAH
patients
120 PAH
patients
120 PAH
patients
24 controls 24 controls24 controls
Diagnostic LASSO modelling LASSO Modeltesting
Figure 1. Study design. Three hundred fifty-nine consecutively recruited patients with pulmonary
arterial hypertension (PAH) from the UK National Cohort study of PAH were randomized into three
groups. Age- and sex-matched control subjects for each group were then identified from the same
study. The first two groups were analyzed separately for RNA discovery and RNA validation and then
combined for modeling of the best combination of RNAs to distinguish between control subjects and
PAH. This model was then tested in the final group of individuals. All patients were combined for
subsequent clinical analyses. LASSO= least absolute shrinkage and selection operator.
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discovery and first validation groups but
found that no transcripts consistently
distinguished responders and
nonresponders and that none of the
previously implicated RNAs were even
nominally different (Table E7).
Comparison with Differentially
Expressed Genes Identified in
Previous Studies
A meta-analysis of previous transcriptomic
studies in blood samples from patients with
PAH (6) and a study of PAH lung tissue
samples (7) were compared with results
from the current RNAseq analysis.
Four hundred sixteen out of the 507 top
dysregulated genes from the current
RNAseq study were present in the PAH
blood transcriptomic meta-analysis (6). Out
of those, 300/416 (72%) were directionally
consistent with results from the current
RNAseq study. One hundred twenty-six out
of 300 (42%) of these were nominally
significant and 70 met FDR corrected
significance. Thirty-seven out of 70 genes
also met FDR corrected significance in the
idiopathic PAH subgroup analysis from
that same study (Table E8).
Three hundred seventy-two out of the
507 top dysregulated genes from the current
RNAseq study were present in the lung
tissue microarray study and 161/372 (43%)
were also directionally consistent. Forty-one
out of 161 (25%) genes were nominally
significant and 26 met FDR corrected
significance (Table E9). Only one gene was
found to be dysregulated in patients with
PAH across all three studies: AMD1
(encoding a polyamine biosynthesis
intermediate enzyme, adenosylmethionine
decarboxylase 1) was consistently lower in
PAH.
Functional Characterization of RNAs
Related to PAH
Of the 507 RNAs found to be differentially
expressed in PAH, 435 were present in
A
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Figure 2. Identification of RNAs with different levels in patients with pulmonary arterial hypertension (PAH) and control subjects. (A and B) Volcano plot of
RNA log fold differences between PAH and control subjects in discovery (A) and validation (B) analyses. Selected genes were identified in further analyses
presented throughout the manuscript including modeling, external validation, and Mendelian randomization. (C and D) Box plots of SMAD5 (C) and TRPC1
(D) levels (log10 reads) in control subjects and patients with PAH in the RNA discovery, validation, and model validation (validation 2) analysis groups.
Horizontal dashed lines in C and D indicate the median level in healthy control subjects.
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the functional annotations in DAVID.
Enrichment of DNA-binding TFs
(transcription factors), such as HIF1a
(hypoxia-inducible factor 1a) and KLF10
(Kru¨ppel-like factor 10), and many zinc
finger–containing TFs was observed
compared with a background of the genes
detected (Table E10). The Ingenuity
Knowledge Base mapped 505/507
transcripts. Double-stranded DNA repair,
T-cell receptor, PI3K signaling in B
lymphocytes, the role of JAK family kinases
in IL6-type cytokine signaling and hypoxia
signaling were among the top canonical
pathways identified by IPA (Figure E5 and
Table E11). AMD1, the only gene in
common between the current RNAseq
study, the recent lung tissue microarray
study and the gene expression meta-
analysis, was part of the top IPA gene
network (Figure E6).
MR Analysis for Association of RNAs
with PAH Development
To determine which of the 507 RNAs
associated with PAH are most likely to
be causal in disease pathogenesis, we
performed a two-sample MR analysis using
whole-blood eQTL from two population-
based studies (15, 16) and summary
statistics from a published PAH genome-
wide association study of 2,085 patients
with PAH and 9,659 control subjects (8).
MR analysis determines whether genetic
variation associated with a trait (e.g., high
or low RNA expression) is itself associated
with a phenotype, in this case the
development of PAH. In this exploratory
analysis in which eQTL were available for
293/507 RNAs, two genes, SESN1 (Sestrin-
1) and SMAD5, reached nominal
significance using eQTL in both data sets
(15, 16); eleven more reached nominal
significance using eQTL from one or the
other of the two studies (Tables E12 and
E13).
The SMAD5 eQTL SNP rs4146187
was clearly associated with SMAD5 RNA
levels in patients with PAH in this study
(P= 3.563 1026, Figure 5; gnomAD
database allele frequency in non-Finnish
European population = 0.275). Patients with
the A/A genotype had comparable SMAD5
RNA levels to control subjects, whereas
patients with the C/C genotype had a
median 18% lower SMAD5 RNA level. The
C/C genotype was present in 49.4% of
patients with PAH, and in the PAH
genome-wide association study (8),
each copy of the A allele (associated
with higher SMAD5 levels) was associated
with an 8.5% reduction in the risk of
developing PAH (odds ratio, 0.915; 95%
confidence interval, 0.846–0.990;
P= 0.0266). SMAD5 levels were similarly
reduced in patients with PAH with and
without pathogenic BMPR2 variants
(Figure E7A), supporting the observation
that impaired signaling in the BMPR2
pathway is more common in PAH than
rare mutations in BMPR2 suggest. The
PAH RNA model score was similarly
elevated in patients with PAH with and
without pathogenic BMPR2 variants
(Figure E7B).
Discussion
Here we report an RNA signature that
separates idiopathic and heritable PAH
from healthy individuals. The signature also
stratifies patients according to disease
severity and risk of early death, adding
plausibility to its association with PAH.
Several of the discriminating mRNAs
encode TFs, including SMAD5, HIF-1a and
KLF10. MR analysis to integrate genomic
data and identify underlying pathogenic
signaling pathways revealed that genetic
variants associated with lower expression
levels of SMAD5 are more common in
patients with PAH.
MR is a powerful tool for separating
cause from consequence, as an individual’s
genetic status predates the development of
PAH. We harnessed genetic data from a
published international genome-wide
association study (8) and information on
previously identified eQTL, common
genetic variants that alter gene expression
levels, from large published studies in
whole-blood RNA samples (15, 16). The
identification of SMAD5 by this unbiased
strategy has biological plausibility as
SMAD5 encodes an intracellular
transcriptional modulator that is
activated by ligand binding of BMPR2,
the most common genetic risk factor in
heritable PAH (3). SMAD5 also has BMP-
independent roles, including regulation of
cellular metabolism, directly interacting
with hexokinase to increase glycolysis,
and responding to changes in
intracellular pH (20). SMAD5 also
controls levels of the master iron
regulator hepcidin (21), which may be
elevated and drive iron deficiency
associated with poor outcomes in PAH
(22). Novel therapeutics under
development target restoration of
BMPR2 signaling in a variety of
ways, including ligand or coactivator
replacement and allowing read-through
of premature stop codons (23–25).
Specificity
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Figure 3. Least absolute shrinkage and selection operator (LASSO) model performance in an
independent validation group of age- and sex-matched subjects. (A) Box plot showing LASSO model
scores for control subjects (n=24) and patients with pulmonary arterial hypertension (PAH) (n=119).
(B) Receiver operating curve showing the performance of LASSO model scores for determining PAH
status in the model validation group.
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Whole-blood SMAD5 profiling may
represent an accessible measurement of
BMPR2 pathway dysfunction in patients
with PAH.
We were able to externally validate
our findings with a meta-analysis of
published PAH blood transcriptome
studies (6) and a PAH lung RNA profiling
study (7). The concordance of our whole-
blood RNAseq findings is better with
blood transcriptomics than with lung
tissue data, as might be expected.
AMD1 was the only gene consistently
dysregulated in both these studies and our
data set, with lower levels in PAH samples
in all three studies. AMD1 encodes a
key enzyme controlling the supply of
decarboxylated S-adenosylmethionine for
polyamine biosynthesis and is regulated
by several mechanisms, including
increased protein degradation in the
presence of elevated polyamines and
the inhibition of mRNA translation
by spermidine and spermine (26).
We have previously demonstrated
that elevated circulating levels of
polyamine metabolites, such as
acisoga, 4-acetamidobutanoate, and
N-acetylputrescine, are associated with
poor outcomes in PAH (4). Reduced AMD1
B
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Figure 4. Diagnostic RNA model and survival in pulmonary arterial hypertension (PAH). (A) Box plot of LASSO model score in control subjects and
patients with PAH separated by survival status during follow-up. Dashed line shows the cutoff that identified 88.9% of nonsurviving patients with PAH.
(B) Kaplan-Meier survival plot separating patients on the basis of the 88.9% sensitive cutoff. (C) Box plot of RNA model score in healthy volunteers and
patients with PAH divided by WHO functional class. (D) Box plot of RNA model score in patients with PAH divided by presence of low, intermediate, or high
levels of cardiac biomarkers BNP (brain natriuretic peptide) (,50, 50–300, or .300 pg/ml) or NT-proBNP (N-terminal pro-brain natriuretic peptide) (,300,
300–1,400, or .1,400 pg/ml), as per European guidelines for PAH assessment. LASSO= least absolute shrinkage and selection operator; WHO=World
Health Organization.
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expression in patients with PAH may be
in part due to negative feedback from
elevated polyamines. These data contrast
with observations in hypoxic rodents.
Amd1 expression is increased in hypoxic
animals, and both AMD11/2 mice and
mice treated with the AMD1 inhibitor,
SAM486a, were partially protected from
the development of hypoxic PH (27).
Interestingly, TRPC1 transcript levels
were also reduced in PAH, in contrast
to findings in hypoxic mice (18). This
might reflect the limitations of the
hypoxic rodent as a model of human
PAH. Support for further investigation
of polyamine metabolism in PAH comes
from the recent association of rare
deleterious mutations in ATP13A3
with PAH (3). ATP13A3 is linked
with polyamine biosynthesis and is a
potential target for drug development
(28).
Many of the transcripts that passed
robust statistical evaluation in this study are
novel. We identified three specific long
noncoding RNAs that are reduced in PAH
and associated with poor outcomes. These
transcripts are not well studied, and their
role in regulating lysosomal proton pump
protein ATP6V0E2, protein tyrosine
phosphatase PTP4A2, or small nuclear
ribonucleoprotein-associated protein N
remain to be established. Their association
with survival selects these out as worthy
of further investigation. In addition to
suggesting biological relevance, the
association of the RNA model, developed to
distinguish PAH from control subjects, with
survival and disease severity in patients with
PAH suggests that the differences observed
could be useful to identify patients who
may require a more aggressive treatment
strategy, such as upfront triple therapy (29).
This strategy could also be used to prioritize
patients more likely to have events to power
clinical trials. RNA profiles and, in
particular, RNAs with known eQTLs,
could be of further use in clinical trial
design to identify patients more likely to
respond to specific therapeutics. It would
be of great interest, for example, to
observe whether patients with lower
SMAD5 levels, or simply with the variant
associated with lower SMAD5 levels,
showed a differential response to novel
therapeutics targeting relevant signaling,
such as the TGF-b ligand trap,
Sotatercept.
There is considerable interest in
developing a biochemical test to identify
patients with PAH who respond well to
calcium antagonists that would supersede
the current test, namely, an acute
vasodilator challenge while undergoing
cardiac catheterization. In contrast to
previous reports, we were unable to
demonstrate the association of a
peripheral transcript signature to
vasoresponder status, including
previously studied RNAs (19). A strength
of our study is the number of patients
studied. Previous reports have relied on
much smaller patient numbers. That we
were able to demonstrate consistency
between our main analysis results and
those of a recently published meta-
analysis of PAH blood transcriptome
studies (6) suggests our methodological
approaches are robust.
One of the limitations of sampling
whole blood to derive transcripts is that
samples comprise a mixed population of
cells. We used established deconvolution
methods to correct for potential
confounding in RNA expression analysis. In
support of the validity of this approach, we
noted altered numbers of regulatory T cells
and CD81 T cells in patients with PAH,
consistent with previous reports (30, 31),
although there is debate on precise
changes in cell subpopulations and
this may be due in part to differing
methodologies and definitions of cell
types (32).
This study does not assess the role of
post-translational modifications in the
pathogenesis of PAH, which could add
further information to the circulating
transcriptome. It is important that further
mechanistic studies consider the role of
the genes highlighted in this study in the
tissues of primary interest, namely, the
lung and heart. The study design included
more patient samples than control
subjects to account for the higher
heterogeneity typically observed in
patient populations. This heterogeneity is
observed in the overlap in box plots of
individual RNA levels or scores between
subsets of patients with PAH and control
subjects and emphasizes the importance
of using any molecular markers in
combination with best practice clinical
assessments. We chose to use LASSO
regression modeling not only as it is
known to perform well in these kinds of
data sets but also because it is widely
applied and often easier to interpret
than other methodologies. Another
consideration is that the patients
studied here were prevalent cases.
Moreover, all the patients recruited had a
clinical diagnosis of idiopathic, heritable,
or drug-induced PAH. It would be of
interest to sample patients with other
presentations of PAH and other
cardiopulmonary diseases to better
understand the clinical utility of our RNA
signature.
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Figure 5. Whole-blood RNA levels of SMAD5 in control subjects and patients with pulmonary arterial
hypertension stratified by genotype at the SMAD5 expression quantitative trait locus rs4146187.
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In summary, we report a whole-
blood RNA profile that distinguishes
patients with PAH from healthy control
subjects and reflects disease severity.
Integration with genomic data suggests
that SMAD5 is important in the
development of PAH, prioritizing
restoration of normal SMAD5
function as a target for therapeutic
intervention. n
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